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Abstract 
Objectives: Internationally, funders require stakeholder involvement throughout Health 
Technology Assessment (HTA). We report successes, challenges and lessons learned from extensive 
stakeholder involvement throughout a palliative care case study that demonstrates new concepts 
and methods for HTA.  
Methods:  ?ƐƚĞƉ  ‘/Ed'Zd-,dDŽĚĞů ?ĚĞǀĞůŽƉĞĚǁŝƚŚŝŶƚŚĞ/Ed'Zd-HTA project guided 
the case study. Using convenience or purposive sampling or directly / indirectly identifying and 
approaching individuals / groups, stakeholders participated in qualitative research or consultation 
meetings. ƵƌŝŶŐƐĐŽƉŝŶŐ ? ? ? ?ƐƚĂŬĞŚŽůĚĞƌƐ ?ĂŐĞĚA? ? ?ŝn seven countries (England, Italy, Germany, 
The Netherlands, Norway, Lithuania and Poland), highlighted key issues in palliative care that 
assisted identification of the intervention and comparator. Subsequently stakeholders in four 
countries participated in face-face, telephone or video-Skype meetings to inform evidence 
collection and / or review assessment results. A rapid applicability assessment to identify 
contextual and implementation barriers and enablers for the case study findings involved 12 
professionals in the three countries. Finally, 13 stakeholders participated in a mock decision making 
meeting in England. 
Results: Views about the best methods of stakeholder involvement vary internationally. 
Stakeholders make valuable contributions in all stages of HTA; assisting decision-making about 
interventions, comparators, research questions; providing evidence and insights into findings, gap 
analyses and applicability assessments. Key challenges exist regarding inclusivity, time and resource 
utilisation.  
Conclusion: Stakeholder involvement is feasible and worthwhile throughout HTA, sometimes 
providing unique insights. Various methods can be used to include stakeholders, although 
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challenges exist.  Recognition of stakeholder expertise and further guidance about stakeholder 
consultation methods is needed.  
Keywords: Stakeholder Involvement, Health Technology Assessment; palliative care. 
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INTRODUCTION:  
Stakeholder involvement in Health Technology Assessment (HTA) is advocated internationally (1). 
StakeholderƐ ĂƌĞ  “ŝŶĚŝǀŝĚƵĂůƐ ? ŐƌŽƵƉƐ ? Žƌ ŽƌŐĂŶŝǌĂƚŝŽŶƐ ǁŚŝĐŚ ŶŽƚ ŽŶůǇ ƐŚĂƌĞ ƚŚĞ ďĞŶĞĮƚƐ ŽĨ ƚŚĞ
topic under scrutiny, but who can potentially affect the goals or the performance of a sector, plan, 
ŽƌƉŽůŝĐǇ ?  ?2, p.85). Hence, stakeholders include lay people (e.g. patients, family members, carers 
or representatives of patient organisations), professionals (e.g. health and social care staff, 
academics) and others (e.g. volunteers, support groups) with an interest in the topic. Funding 
bodies such as the National Institute for Health Research (NIHR) in England and the Research 
Council in Norway require patient and public involvement in grant applications and throughout the 
Health Technology Assessment (HTA).   
Creating opportunities for stakeholder involvement in HTA and ƉƌŽǀŝĚŝŶŐ Ă  ‘ǀŽŝĐĞ ? ĨŽƌ ŝŶƚĞƌĞƐƚĞĚ
parties in decision making is important (3) as this potentially ensures shared key priorities are 
addressed and research findings are translated into practice (4). To avoid paying lip service to 
stakeholder involvement, this needs to be undertaken for a legitimate purpose and be 
appropriately inclusive for the HTA being undertaken (e.g. including stakeholders from various 
services) (2). However, including stakeholders in HTA and decision making is challenging as policy 
and decision makers are faced with swift technological developments and the increasing 
requirement to provide rapid assessments of complex health technologies (5). The situation is 
confounded by increasing pressures to demonstrate transparency in decision making processes (2). 
Some reluctance to involve stakeholders has been reported (2), perhaps due to concerns about 
introducing bias to the HTA process (5). 
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Despite these challenges, examples of stakeholder involvement exist in some Health Technology 
Assessments, for example, Cochlear implant, albeit that differences in stakeholder views give rise 
to continuing debates about ethically contested issues (6). Indeed, little guidance exists about 
stakeholder involvement in HTA, especially with regard to those with rare diseases or affected by 
sensitive issues, such as palliative care. That said, some guidance has been published about patient 
and public involvement in health and social care research by INVOLVE, in the U.K. (7). INVOLVE is 
funded by the National Institute for Health Research (NIHR) in England. Additionally, Popay and 
Collins (8) have published guidance for evaluating the impact of public involvement in research. 
Although useful, such guidance does not make reference to other stakeholders.  Hence, given 
policy and funder expectations, a number of questions arise about stakeholder involvement, 
notably who to involve, when and how to involve them (9). Additionally, questions also arise about 
the value and impact of stakeholder involvement throughout HTA (10).  
We involved palliative care stakeholders in a large European project (INTEGRATE-HTA) that 
developed concepts and methods for the integrated assessment of complex technologies because 
policy-makers need better tools to support their decision making in this area (see 
http://www.integrate-hta.eu/). To demonstrate their feasibility and value, the concepts and 
methods developed in the project were applied in a case study that evaluated models of palliative 
care service delivery as an example of a complex technology (11).  We assessed home based 
models of palliative care with and without an additional, explicit and intentional component of 
informal carer  ‘support ?  ?ŬŶŽǁŶ ĂƐ  ‘ƌĞŝŶĨŽƌĐĞĚ ? ĂŶĚ  ‘ŶŽŶ-ƌĞŝ ĨŽƌĐĞĚ ? ŵodels of home care 
respecƚŝǀĞůǇ ĂĨƚĞƌ 'ŽŵĞƐ ? ĂůĂŶǌĂŶŝ ? ƵƌŝĂůĞ Ğƚ Ăů ?Ɛ  ? ? ? ? ŽĐŚƌĂŶĞ ƌĞǀŝĞǁ ?.  ĂƌĞƌ  ‘ƐƵƉƉŽƌƚ ? ŵĂǇ
include education, counselling or other supportive interventions.  
The palliative care case study demonstrating the application of some of the INTEGRATE-HTA 
methodological guidances was undertaken in England for pragmatic reasons as palliative care 
provision differs throughout Europe. The case study was designed to inform the following research 
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ƋƵĞƐƚŝŽŶ P  ‘Are reinforced models of home based palliative care acceptable, feasible, appropriate, 
meaningful, effective, cost-effective models for providing patient-centred palliative care (compared 
to non-reinforced models of home based palliative care) in adults (defined as those aged 18 years 
old and over) and their families? ?Stakeholder involvement was an important source of evidence in 
the case study as, following the development of methodological guidance. This paper reports on 
the extensive stakeholder involvement that occurred throughout the palliative care case study and 
reflects on the successes, challenges and lessons learned from stakeholder involvement at each 
stage of the HTA.  
METHODS 
The 5 step INTEGRATE-HTA Model (13) which enables integration of relevant assessment aspects 
was used to guide the application of new concepts and methods in the palliative care case study. 
Steps 1 and 2 define the scope of the HTA, Step 3 coordinates the assessment of evidence. Steps 4 
and 5 structure the applicability appraisal and final HTA recommendation. Stakeholder involvement 
was identified as important from the outset of the study and  ?hZK ? ? ? ? ?ǁĂƐĂǀĂŝůĂďůĞĨŽƌ
stakeholder involvement in each country. The amount spent in each country varied as some 
stakeholders declined payment.  
 
Step 1 and 2: Stakeholder involvement in scoping the palliative care case study  
Stakeholders participated in scoping for the palliative care case study in seven countries (England, 
Italy, Germany, The Netherlands, Norway, Lithuania and Poland). Because policy, philosophy, 
expectations and consequently methodological, ethical and practical issues for stakeholder 
involvement and palliative care research varies in each country, researchers used locally advocated 
methods for stakeholder involvement. Hence, either a consultative approach based on the National 
Institute for Health and Care Excellence (NICE) guidance (14) or a qualitative research approach 
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was used to involve stakeholders in scoping in each country.  The methods and findings of the 
scoping phase have been previously reported (15). 
  To identify their perspectives about key issues and topics of importance for palliative care at the 
outset of the case study, a local co-ordinator (member of the INTEGRATE-HTA team or known 
associate) led stakeholder involvement in each country. The local co-ordinator ensured that the 
identification and recruitment of lay people and professionals was appropriate for the local context 
and approach to stakeholder involvement adopted. Some stakeholders were identified by 
INTEGRATE-HTA researchers with palliative care experience and knowledge of individuals or groups 
with lay or professional expertise in the field.  The co-ordinator in each country approached known 
stakeholders directly and sought the assistance of managers or a key professional in services 
delivering palliative care to identify and recruit previously unknown stakeholders to the project. To 
ensure that lay people had relevant experience, we recruited them from local palliative care 
services or groups known to have an interest in, or experience of, palliative care. 
We involved a total of 132 stakeholders (82 profeƐƐŝŽŶĂůƐĂŶĚ ? ? ‘ůĂǇ ?ƉĞŽƉůĞ ?aged A? ? ?ŝŶĂůůƐĞǀĞŶ
countries between May and Sept 2013. >ĂǇƐƚĂŬĞŚŽůĚĞƌƐŝŶĐůƵĚĞƉĂƚŝĞŶƚƐ ? ?ƐŽŵĞǁŝƚŚĞǆƉĞƌŝĞŶĐĞĂƐ
a patient and carer of someone with palliative care needs; carers, ex-carers, family members and 
friends of someone with palliative care needs as well as members of palliative care group / 
associations and volunteers (among lay stakeholders in Poland). Professional stakeholders include 
clinicians; researchers; staff with a dual clinician and researcher role; managers, social worker and 
pastoral care specialist and volunteers (among professional stakeholders in Italy). Where known, 
most stakeholders were white females, with lay stakeholders aged 27-89 and professionals aged 
28-69.  Stakeholders participated in either individual face- to- face or telephone meetings or 
interviews, group meetings or focus groups (see Table 1). Stakeholder consultation occurred in 
meetings where information was collected and summarised using the EUnetHTA Core Model® (16) 
as an overarching framework. Individual interviews or focus group meetings were conducted using 
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semi-structured interviews within a qualitative approach in keeping with local tradition and 
researcher preference. Thematic analysis was used to identify key issues across countries (See 15 
for further details).  
Step 3 Stakeholder involvement in evidence collection and assessment 
Between April and June 2015, stakeholders both provided information that informed evidence 
collection and participated in the review of assessment results as outlined below (see Table 2).   
Some stakeholders had previously taken part in scoping of the palliative care case study (steps 1 
and 2). Lay stakeholders who were members of a local palliative care advisory group or cancer 
research group in England were invited to participate by the local co-ordinator. Professional 
stakeholders were either directly identified and recruited to step 3 by members of the INTEGRATE-
HTA project team or they volunteered to participate having been given information about 
opportunities to participate in the research by service managers who distributed information to 
them on behalf of the INTEGRATE-HTA team.  However, time and resource constraints meant that 
we were unable to involve lay stakeholders (i.e. patients, lay caregivers or other interested parties) 
in all assessments.  
Economics  W A consultative approach was used to involve stakeholders in the economic assessment 
(17) and several methods were used to elicit information including email communication, 
telephone discussions, face to face meetings, and workshops. Nine stakeholders (8 professionals 
and 1 female lay person with experience as a patient and carer) contributed to the two workshops 
for the economic evaluation in England, both guided by a semi structured consultation guide. In the 
first workshop stakeholders provided information that informed an understanding of the problem 
and conceptual modelling. In the second workshop, stakeholders provided data to fill gaps in the 
economic model and discussed the results of the economic analysis.  
Socio-cultural  W Some steps from the INTEGRATE-HTA guidance to assess socio-cultural aspects 
(17) of HBPC and rHBPC, specifically user-professional relationships, were applied through 
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consulting nine stakeholders in England using semi structured consultation guides. Two researchers 
(one with sociological and health sciences expertise (German) and one with palliative care 
expertise (English native speaker) were involved.  Two professional stakeholders participated in 
individual consultations lasting about an hour via telephone. Subsequently, one face-to-face group 
consultation, lasting about two hours, took place with four lay stakeholders (1 female with 
experience as a patient and carer; 1 female relative and 2 male ex-carers) in England initially using 
an open question guide. At the end of the meeting, a prioritisation exercise took place. The same 
researchers completed a second group consultation, lasting about an hour, with three 
professionals in England via video-Skype ƚŽŐĂŝŶĂĚĞĞƉĞƌƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨ “ƚŚĞƵƐĞr-professional-
ƌĞůĂƚŝŽŶƐŚŝƉ ĂŶĚ ĚĞĐŝƐŝŽŶ ŵĂŬŝŶŐ ? ?  ƉĂƌƚŝĐŝƉĂƚŽƌǇ ĂƉƉƌŽĂĐŚǁĂƐ ƵƐĞĚ ƉƌŝŵĂƌŝůǇ ƚŽ ƚĞƐƚ ŝĨ
stakeholders could apply the typology developed in the socio-cultural framework within the 
consultation. Prior to the meeting, documents about the content of the consultation (including the 
framework to be discussed) were shared.  
Ethical  W The information provided by stakeholders in the scoping phase of the case study, socio-
cultural and economic assessments was subsequently used to inform an assessment of the 
complexity of, and ethical issues associated with, (reinforced) home based palliative care by one 
researcher using a procedural framework devised by Lysdahl et al., (17).  
Effectiveness - To compare reinforced with non-reinforced home based palliative care 
interventions, 'ŽŵĞƐ ?ĂůĂŶǌĂŶŝ ?ƵƌŝĂůĞĞƚĂů ?Ɛ ? ? ? ?systematic review was updated as part of the 
INTEGRATE-HTA guidance to assess effectiveness aspects (18). Harvest plots were created to 
portray heterogeneous evidence in a clear, transparent way as meta-analysis was less appropriate. 
The harvest plots were used as a basis for a gap-analysis of the existing literature, which was 
subsequently used to inform individual semi-structured telephone consultation with four 
professional stakeholders (including male and female researchers and practitioners) from three 
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countries (England, Germany and the Netherlands). No lay stakeholders were involved in the rapid 
effectiveness assessment due to time and resource constraints.  
Patient preferences and moderators of treatment outcome - A summary of the results from the 
assessment of both patient preferences and moderators of treatment outcome was presented to 
an advisory panel of seven stakeholders in England that consisted of two male ex-carers, aged 63 
and 74 and five experienced palliative care nurses working in a range of settings. The meeting took 
place via video-Skype with researchers based in the Netherlands and the support of a researcher 
based in England who was present in the group meeting. Using a semi-structured consultation 
guide, stakeholders were asked to validate the assessment findings and to provide an explanation 
for these or additional insights.  
Legal  W (There was no stakeholder consultation in the legal assessment)  
Step 4 Stakeholder involvement in appraisal/applicability 
Rapid applicability assessment - a rapid applicability assessment was undertaken with 12 professionals (2 in the 
U.K., 2 in Germany and 8 in Poland) to identify contextual and implementation barriers and enablers specific to the 
application of the demonstration HTA findings. All professional stakeholders were directly identified and recruited 
to step 4 by members of the INTEGRATE-HTA project team or their known associates who assisted with the project 
locally. No lay stakeholders were involved in the rapid applicability assessment due to time and resource 
constraints. In the U.K. and Germany, one researcher with HTA experience conducted individual meetings using a 
consultation guide by telephone, except for one professional, who participated in a face-to-face meeting.  The 
consultations lasted about an hour, ranging from 55-90 minutes. In Poland, a previously informed palliative care 
expert facilitated a panel consultation lasting about four hours with 8 professionals. The professionals were 
encouraged to discuss the issues raised for each domain identified in the consultation guide and provide additional 
information. All information was concurrently collected, summarised, and presented on a PowerPoint Sheet for 
validation by the expert panel.  
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Step 5 Stakeholder involvement in decision making - Step 5 results in the HTA conclusion and 
recommendations. A group of 13 stakeholders (11 professionals involved in commissioning end of 
life services and 2 lay stakeholders in England) participated in a mock decision making meeting. 
Professional stakeholders were recruited to step 5 by the chair of the commissioning group who 
was approached directly by the local co-ordinator in England. Lay stakeholders (one male and one 
female, both ex-carers) were members of the palliative care advisory group who were also invited 
to participate in the meeting by the local co-ordinator with the agreement of the chair of the 
commissioning group as the mock decision making meeting took place instead of the ŐƌŽƵƉ ?Ɛ
scheduled meeting. Multiple Criteria Decision Analysis (MCDA) may be used to support decision-
making in HTA. MCDA guides stakeholders to weight the assessment criteria (effectiveness, cost 
effectiveness etc.) based on a generic description of them. In the consultation meeting, stakeholder 
were presented with the results of the assessments. Stakeholders then scored the HTA results on a 
scale from +5 to -5 to indicate whether the intervention (i.e. reinforced home based palliative care) 
ŝƐ “ƐŝŐŶŝĨŝĐĂŶƚůǇďĞƚƚĞƌ ?Žƌ “ƐŝŐŶŝĨŝĐĂŶƚůǇǁŽƌƐĞ ?ƚŚĂŶŶŽ -reinforced home based palliative care. 
Scoring stimulated open discussion amongst group members.  
RESULTS 
Stakeholder involvement in scoping the palliative care case study  
For a detailed report about stakeholder involvement in scoping of the palliative care case study for 
the INTEGRATE-HTA project, please see Brereton et al (15). In terms of successes, we involved a 
large number (n=182) of palliative care stakeholders in seven European countries in scoping. In 
terms of added value, stakeholders identified twenty-three issues that were common to three or 
more countries. Stakeholder involvement (along with a review of review level evidence) informed 
ƚŚĞƉƌŽũĞĐƚ ?ƐŵĂŝŶƌĞƐĞĂƌĐŚƋƵĞƐƚŝŽŶďǇĞŶĂďůŝŶŐƵƐƚŽŝĚĞŶƚŝĨǇ ‘ƌĞŝŶĨŽƌĐĞĚ ?ĂŶĚ ‘ŶŽŶ-ƌĞŝŶĨŽƌĐĞĚ ?
ŵŽĚĞůƐŽĨŚŽŵĞĐĂƌĞĂƐƚŚĞŝŶƚĞƌǀĞŶƚŝŽŶĂŶĚĐŽŵƉĂƌĂƚŽƌŽĨŝŶƚĞƌĞƐƚ ?ůƚŚŽƵŐŚƌĞŝŶĨŽƌĐĞĚ ?ŵŽĚĞůƐ
of home palliative care explicitly address only two of the issues raised by stakeholders in several 
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countries (i.e. the need to increase home care and the need for caregiver training/support), 
researchers can be confident that the intervention is important to both lay and professional 
stakeholders internationally. The remaining issues ŝŶĐƌĞĂƐĞĚƚŚĞƌĞƐĞĂƌĐŚƚĞĂŵ ?ƐĂǁĂƌĞŶĞƐƐŽĨŬĞy 
issues in palliative care as some HTA researchers had limited experience in the field. The 
information provided also assisted the development of sub questions for use in the case study (e.g. 
for the socio-cultural aspects which focused on the user-professional-relationship and decision 
making). Additionally, we subsequently used stakeholder information provided during the scoping 
phase to inform a logic model (see 19) and specific assessments, notably the complexity and ethical 
assessments related to home based palliative care within the HTA.  
 
Key challenges exist in ensuring inclusivity of all stakeholder groups  W for example, enabling 
stakeholders who are very ill to contribute to HTA. Additional challenges exist in terms of identifying 
stakeholders because some provide insights from the perspective of both a patient and carer, 
having fulfilled both roles and others, notably volunteers, were identified as professionals in some 
countries and lay people in others. The use of different approaches to stakeholder involvement 
across countries posed a number of challenges, notably for the collective analysis of information / 
data. Not only does the terminology for consultation and qualitative research differ but there is a 
need for guidance about how to analyse the collective findings from these different paradigms.  
We learned that the underlying philosophy and views of appropriate and feasible methods of 
stakeholder involvement vary internationally, resulting in different ethical requirements and 
practical considerations. However, stakeholders, including patients and families undergoing 
palliative care, can inform project decision making. Methods for stakeholder involvement, 
especially consultation, need further development. 
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Stakeholder involvement in evidence collection and assessment 
We successfully involved a number of lay and professional stakeholders in evidence collection and 
assessment of HTA findings for a number of aspects of the palliative care case study.  Irrespective 
of the range of face-face or remote (e.g. telephone, video-Skype) methods and activities used, 
when both when both lay and professional stakeholders participated in meetings, they worked well 
together. Stakeholders added value to the HTA by drawing on their experiential knowledge to 
provide additional insights for researchers in terms of informing the assessment; prioritizing issues; 
informing gap analysis, validating and interpreting assessment findings. For example, stakeholders 
provided economic information that is not readily available elsewhere, making their involvement in 
a series of workshops and meetings worthwhile. Stakeholder consultations provided fresh 
perspectives on the effectiveness evidence, which indicated no effect of reinforced care compared 
to non-reinforced care for most patient and carer outcomes. They also highlighted implications for 
practice and further research. For example, stakeholders emphasized the need to develop a clear 
understanding of non-reinforced (i.e. usual care) as the nature of palliative care means that this is 
likely to be tailored to provide individualized, holistic care for the family. Such understandings are 
important to identifying what alternative, additional services may be effective. They also suggested 
alternative evaluative designs are needed in palliative care research as the outcomes frequently 
measured may not reflect the purpose of interventions such as reinforced home care.  
Although stakeholder involvement in some assessments (e.g. effectiveness) did not create much 
additional work for researchers or stakeholders, it was a resource intensive exercise in terms of 
time for both stakeholders and researchers in some other assessments (e.g. economics). Some 
assessments (e.g. the socio-cultural assessment) proved challenging because they involved several 
steps and different stakeholders in each step. In such situations, stakeholders require careful 
preparation with regard to information they receive in advance of the meetings.  
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A number of lessons were learned, notably that interactive forms of communication were the most 
productive forms of stakeholder involvement. Successful stakeholder involvement probably relies 
on the perceived relevance of the decision problem and requires those taking part to be 
enthusiastic and committed to become, and stay involved  W especially when more than one 
meeting or workshop is planned. Careful planning is required to ensure stakeholders receive 
sufficient information and are adequately prepared for each involvement activity.  
Stakeholder involvement in a rapid applicability assessment 
Appraisal / applicability assessments were successfully completed using various methods (face-face 
and telephone meetings or panel discussions) in three countries. The findings added value by 
indicating that organizational and structural barriers need to be considered in all three countries to 
ensure the applicability of rHBPC. The underlying issue for many of the stated barriers concerning 
the implementation of rHBPC is the limited availability of financial resources. Involving 
stakeholders in a group meeting provides the opportunity to validate findings with experts; assists 
in assuring the quality of information used in the rapid assessment and may provide deeper 
insights into the applicability of the assessed intervention. However, the depth of retrieved 
information does not necessarily decrease by consulting experts in one-by-one consultations. 
A key challenge is identifying relevant stakeholders who have sufficient time to attend a lengthy 
meeting for the rapid assessment (when panel meetings are used). Again, we learned that various 
methods can be used to involve stakeholders in applicability assessments.  
Stakeholder involvement in mock decision making  
tĞƐƵĐĐĞƐƐĨƵůůǇĞŶŐĂŐĞĚďŽƚŚůĂǇĂŶĚƉƌŽĨĞƐƐŝŽŶĂůƐƚĂŬĞŚŽůĚĞƌƐŝŶĂĨŝŶĂů ‘ŵŽĐŬ ?ĚĞĐŝƐŝŽŶŵĂŬŝŶŐ
meeting. Although a decision could not be finalised, stakeholders still added value by highlighting a 
number of important issues related to the benefit of rHBPC and the relevant evidence in the case 
study. 
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The final mock decision making meeting posed many challenges as a large amount of information 
needed to be summarised and discussed in a relatively short time. Similarities between the 
intervention and comparator make them difficult for some stakeholders to differentiate even 
though wŽƌŬŝŶŐĚĞĨŝŶŝƚŝŽŶƐŽĨƚŚĞƚĞƌŵƐ ‘ŚŽŵĞďĂƐĞĚƉĂůůŝĂƚŝǀĞĐĂƌĞ ?ĂŶĚ ‘ƌĞŝŶĨŽƌĐĞĚŚŽŵĞďĂƐĞĚ
ƉĂůůŝĂƚŝǀĞĐĂƌĞ ?ǁĞƌĞƉƌŽǀŝĚĞĚ ?ůƚŚŽƵŐŚƚŚĞĚŝĨĨĞƌĞŶĐĞƐŝŶƚŚĞŝŶƚĞƌǀĞŶƚŝŽŶĂŶĚĐŽŵƉĂƌĂƚŽƌǁĞƌĞ
articulated by an experienced practitioners in the meeting, some stakeholders believe that current 
ƉƌĂĐƚŝĐĞŝŶĐůƵĚĞƐƐŽŵĞƉƌŽǀŝƐŝŽŶĨŽƌĐĂƌĞƌƐĂŶĚƚŚĞƌĞĨŽƌĞ ‘ƌĞŝŶĨŽƌĐĞĚ ?ŚŽŵĞďĂƐĞĚƉĂůůŝĂƚŝǀĞĐĂƌĞŝƐ
being provided (which other stakeholders do not believe is the case). Overlaps between categories 
in the assessment criteria existed along with interactions between different assessment aspects. 
External validity, evidence gaps and the need for a well defined, clearly differentiated comparator 
were all issues of concern for stakeholders in the meeting. For final decision-making, these issues 
should be taken into account.  
Discussion  
This paper reports on the successes, challenges and lessons learned about stakeholder involvement 
throughout HTA. Despite successes, and strengths of the project, in terms of our extensive 
involvement of lay and professional stakeholders throughout the palliative care case study, 
inclusivity proved challenging as lay stakeholders were not involved in some assessments. The lack 
of involvement of lay stakeholders in some assessments is undoubtedly a limitation given the 
increasing calls to access public views throughout HTA (20). Furthermore, some groups (e.g. 
volunteers) were under-represented throughout the case study due to resource limitations and 
ease of access which reflects findings of a review of stakeholder involvement in programme 
evaluation (21). Indeed, similar challenges regarding inclusivity in stakeholder involvement are 
recognised within the wider literature, which not only gives rise to concerns about ensuring 
representation of stakeholder interests (2), power (5), fairness (2; 5; 9), legitimacy (2; 5) and 
transparency of decision making (9). Despite inclusivity posing challenges, palliative care provides a 
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ŐŽŽĚĞǆĞŵƉůĂƌĨŽƌŽƚŚĞƌŚĞĂůƚŚĐŽŶĚŝƚŝŽŶƐĂƐƉĂƚŝĞŶƚƐƚĂŬĞŚŽůĚĞƌƐ ?ŚĞĂůƚŚǁŝůůǀĂƌǇƚhroughout the 
disease trajectory and its holistic nature captures the views of others (e.g. family carers) who are 
stakeholders in their own right. Furthermore, palliative care allows inclusion of generalist (i.e. 
practitioners working in palliative care who do not have specialist palliative care qualifications) and 
specialist health and social care professional stakeholders (i.e. practitioners working in palliative 
care who have specialist palliative care qualifications). To be inclusive, researchers require a good 
knowledge of services and the potential stakeholder groups affected by the HTA. Whilst inclusivity 
of stakeholders from a variety of locations potentially increases the value of the HTA findings, 
further guidance is needed about how to maximise stakeholder involvement in HTA and how to 
best acknowledge and address the ethical issues that arise. 
Securing such high levels of stakeholder involvement in seven countries and identifying similarities 
in findings in the scoping phase of the case study provides some confidence that the key issues 
identified by stakeholders are of shared international importance. Several issues identified by 
stakeholders, such as the emphasis on home care are reflected in the international palliative care 
policy and literature (22). The insights gained through the inclusion of heterogeneous stakeholders 
(e.g. patients, family members, clinicians and academics) evidences ways that their expertise 
benefits HTA and researchers involved in HTA. Our case study findings suggest that not only can 
stakeholders help to identify key issues in the field; inform the choice of intervention and 
comparator for assessment, provide evidence and assist the interpretation of findings, they can 
also highlight issues influencing applicability and potentially contribute to decision making. Indeed, 
heterogeneous stakeholder involvement may be of particular value in the assessment of complex 
interventions as this can contribute to understanding how the intervention may interact with 
different health contexts and settings (20).  
Although some authors refer to the benefits of stakeholder expertise for HTA (23), most texts refer 
ƚŽ  ‘ĞǆƉĞƌƚ ?  ?ŝ ?Ğ ? ƉƌŽĨĞƐƐŝŽŶĂů ? ĂŶĚ ůĂǇ ƐƚĂŬĞŚŽůĚĞƌƐ ? ŝŵƉůŝĐŝƚůǇ ƐƵŐŐĞƐƚŝŶŐ ƚŚĂƚ ƉƌŽĨĞƐƐŝŽŶĂůƐ ĂƐ ƚŚĞ
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 ‘ĞǆƉĞƌƚƐ ? ŚĂǀĞ ŐƌĞĂƚĞƌ ? Žƌ more valuable, knowledge and insights than lay stakeholders. It seems 
important to acknowledge that recognise the different expertise of all stakeholders and 
acknowledge that their experiences, views and contributions to HTA are equally valuable. That said, 
further work is needed that clearly illustrates the added value of contributions from each 
stakeholder group.  
Using different approaches (i.e. qualitative research and stakeholder consultation) in the scoping 
phase of the case study, respected local understandings about the best methods of stakeholder 
involvement. However, despite similarity in findings across countries in the scoping phase, analysis 
proved challenging. It is tempting to suggest that there is a need to identify or develop methods of 
stakeholder involvement that are acceptable internationally, so that the findings from cross country 
stakeholder involvement can be more easily compared. However, this would fail to take account of 
differences in healthcare systems and administrative traditions within which HTA organisations 
function in each country (23). Using a range of stakeholder involvement methods throughout the 
HTA successfully enables flexible and responsive information exchange to ensure common 
understandings develop. Indeed, no one method of stakeholder involvement will be suitable in all 
situations, especially when including diverse stakeholder groups, vulnerable or very ill stakeholders. 
Although, the interactive approaches adopted in this project were selected as pragmatic ways of 
eliciting information to demonstrate concepts and methods developed in the INTEGRATE-HTA 
project, they proved useful in demonstrating the feasibility of stakeholder involvement throughout 
HTA and reflect the principles of good practice for stakeholder involvement in the conduct of HTA 
(24). Indeed, involving stakeholders throughout HTA provides the real world data that will 
complement RCT data (20). Feedback from stakeholders involved in our study indicated that 
everyone felt able to contribute to the discussion and learn from their involvement in the project. 
None-the-less, further guidance about stakeholder consultation methods is needed to enhance the 
quality and effectiveness of stakeholder involvement activities.  
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Conclusions:  
This case study suggests that stakeholder involvement is both feasible and worthwhile throughout 
,d ?^ƚĂŬĞŚŽůĚĞƌƐ ?ĞǆƉĞƌŝĞŶĐĞĂŶĚĞǆƉĞƌƚŝƐĞĐĂŶŚĞůƉƚŽŝĚĞŶƚŝĨǇŬĞǇŝƐƐƵĞƐŝŶƚŚĞĨŝĞůĚ ?ŝŶĨŽƌŵƚŚĞ
focus of the assessment (e.g. interventions, comparators, questions and sub questions), provide 
evidence and assist the interpretation of the evidence. Furthermore, stakeholders can highlight 
applicability issues and potentially contribute to decision making. The immediate benefit for HTA 
researchers and stakeholders themselves is potentially more widely realised after decision makers 
have agreed the action, if any, required. Challenges to stakeholder involvement relate to ensuring 
inclusivity, especially for patients and the public, and overcoming resource limitations, notably with 
regard to the time required for such activities in some assessments.  We learned that views of the 
best methods of stakeholder involvement and the associated ethical requirements vary 
internationally and that various methods can be used to involve stakeholders throughout HTA. 
With careful planning, lay and professional stakeholders can be involved throughout HTA and the 
impact of their involvement on the project, researchers and stakeholders themselves could be 
assessed. To minimise potential challenges, researchers need to develop some understanding of 
the local context for stakeholder involvement to be able to comply with ethical requirements, 
adopt appropriate methodologies and address practical issues related to stakeholder involvement. 
Further guidance about stakeholder involvement throughout HTA is required, especially for 
vulnerable or hard to reach groups. We recommend that the experiential and colloquial knowledge 
provided by stakeholders should be recognised by researchers as part of the evidence hierarchy 
and methods developed to evaluate the impact of stakeholder involvement in HTA, especially in 
areas where both the quantity and quality of the evidence is limited. 
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25. Table 1. Background details of the stakeholders involved in scoping in each country. 
 Lay stakeholders Professional stakeholders 
 E n=20 G n=8 I n= 7 Ne n= 
2 
No n= 5 Pn= 8 L* E n=34 G n=7 I n=8 Ne n=12 No n=5  P n=7  L n=9* 
Location Sheffiel
d  W a 
city in 
the 
North of 
England  
City & 
small 
town in 
norther
n 
German
y  
6 
Rome 
(Lazio 
Region
) 
1 Lecce 
(Puglia 
Region
) 
Nijme
gen  
Oslo Bydgosz
cz 
 Across 
England 
& 1 from 
Ireland 
City & 
small 
town in 
northern 
Germany  
6 Rome 
(Lazio 
Region) 
1 Lecce 
(Puglia 
Region) 
Nijmege
n  
Oslo Bydgoszc
z 
Kaunas 
Sex M -10 F-
10  
M-3 F-5 M-2   
F-5 
M-1      
F-1 
M-2      F-
3 
M-0      
F-8 
 M-9      
F25 
M-1     F-
6 
M-3      F-
5 
M-6      
F-6 
M-1     
F-4 
M-4      F-
3 
F-9 
Age  ? 
range  
(mean)  
32-89  40-69 
 
33-72  
 
Did 
not 
ask 
27-81 
 
 
25-65 
 
 28-66  
  
40-69  33-67 Did not 
ask 
50-59  
 
38-52 
 
28-66  
Advisor  
 
P-2 
P & C -1  
C W 2  
Ex-C- 2 
FM  W 6  
Fr -2  
PC 
group -5  
P-4 
FM  W 4  
 
FM  W7  
 
P-2 
 
P - 3 
C  W 2 
PC group 
- 3 
V - 5 
 
 Cl-22 
R  -6 
Cl & R - 5 
M -1 
Cl -4 + 1 
(retired) 
Cl& R  - 1  
M- 1  
 
Cl  W 4  
R  W 3  
V - 1  
Cl  W 6  
Cl& R  - 6  
 
Cl& R  W 
5  
 
Cl  W 3  
Cl & R W 4  
 
Cl 6 (4 
manag
ers) 
Cl& R  W 
1  
SW & 
PCS  W 2  
 
 
Key: E-England; G-Germany; I-Italy; Ne-Netherlands; No-Norway; Pn-Poland; L-Lithuania. 
*In Lithuania, the professionals approached included 3 representatives of patient organisations provided information in lieu of approaching lay stakeholders for two reasons; 1) Patients 
receiving palliative care have a serious health condition and 2) palliative care in Lithuania is relatively new field and competent opinion can express may be more specialist.Lay stakeholders: P:Patient;  P&C: 
patient & carer; C: Carer;  Ex-C: Ex-Carer;  FM: Family member ; Fr: Friend; PC Group : Member of palliative care group / associations; V: volunteers (among lay stakeholders in Poland).  Professional stakeholders: Cl: 
Clinicians; R: Researchers; Cl & R: Clinician & Researcher (dual role); M: Manager, SW & PCS: Social worker and Pastoral Care Specialist; V: volunteers (among professional stakeholders in Italy).   
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Table 2: Background details of the stakeholders involved in evidence collection and assessment, a rapid applicability assessmĞŶƚĂŶĚĂ ?ŵŽĐŬ ?ĚĞĐŝƐŝŽŶ
making meeting. 
 Economics  Socio-cultural  Ethics  Effectiveness  Patient preferences 
& moderators of 
treatment outcome  
Rapid applicability 
assessment  
Mock decision 
making meeting  
Country:  England  England England  E G N England  E G P England 
Advisors:  
  
P- 8  
P & Ex C  W 1  
P  W 2  P  C  W  
Rel  W 1 Ex C  W 2 
P - 3 P- 94 
(approx.)  
Lay  W 51 
P- 2  P- 1  P- 1 P-5 
Ex C 
 W 2  
P-2 P- 2 
Sex:  M-2 
F-7 
F -2 M-2  
F-2  
F- 3  Unknown  W 
mostly female  
M-1 
F-1  
M-1 M-1 M  W 2 F- 5 M M M M- 3  
F - 10 
Total number of 
advisors 
9 9 Approximately 
145 (some 
advisors 
participated in 
both the scoping 
(n=132) and / or 
economics (n=9) 
and socio-cultural 
assessments 
(n=9)).  
4 7 12 13 
 
Key: E-England; G-Germany; I-Italy; Ne-Netherlands; No-Norway; Pn-Poland; L-Lithuania. 
*In Lithuania, the professionals approached included 3 representatives of patient organisations provided information in lieu of approaching lay stakeholders for two reasons; 1) Patients 
receiving palliative care have a serious health condition and 2) palliative care in Lithuania is relatively new field and competent opinion can express may be more specialist.Lay stakeholders: P:Patient;  P&C: 
patient & carer; C: Carer;  Ex-C: Ex-Carer;  FM: Family member ; Fr: Friend; PC Group : Member of palliative care group / associations; V: volunteers (among lay stakeholders in Poland).  Professional stakeholders: Cl: 
Clinicians; R: Researchers; Cl & R: Clinician & Researcher (dual role); M: Manager, SW & PCS: Social worker and Pastoral Care Specialist; V: volunteers (among professional stakeholders in Italy).   
 
 
